Semaglutide: the original GLP-1 analogue

Before tirzepatide's dual action and retatrutide's triple action, there was semaglutide — the compound that turned GLP-1 from a laboratory curiosity into one of the most studied molecules in metabolic science. Understanding it is the natural starting point for the whole modern incretin field.

A single, well-characterised pathway

Semaglutide is a synthetic analogue of GLP-1 (glucagon-like peptide-1), a hormone intestinal cells release in response to food. It is studied as a GLP-1 receptor agonist — a molecule that engages one pathway, central to glucose and appetite signalling in laboratory models. Its single-pathway focus is what makes it the reference point against which dual and triple agonists are compared.

Why it became the reference compound

In the published research literature, semaglutide has been associated with pronounced effects on metabolic markers and body-weight regulation in study models, alongside a long duration of action. Our articles on GLP-1 peptides and GLP-1 analogues place it beside tirzepatide and retatrutide in the research lineage.

Structure and stability

Semaglutide's backbone carries amino-acid substitutions and a fatty-acid chain that slow its breakdown — modifications that give it a far longer half-life than native GLP-1. Our companion article on why modified peptides last longer explains the design. It is supplied as a lyophilised (freeze-dried) powder, the most stable form.

Handling and reconstitution

Semaglutide is reconstituted with bacteriostatic water before use in research. Our reconstitution and storage guide covers the correct method, and every Vela order ships with a free 3 mL vial of bacteriostatic water.

Documented quality

Because semaglutide is such an active research subject, verified identity and purity matter. Every Vela batch is supplied with a certificate of analysis issued within six months of sale.